Veterinary vaccine development from an industrial perspective

被引:37
作者
Heldens, J. G. M. [1 ]
Patel, J. R. [2 ]
Chanter, N. [3 ]
ten Thij, G. J. [1 ]
Gravendijck, M. [4 ]
Schijns, V. E. J. C. [5 ]
Langen, A. [6 ]
Schetters, Th. P. M. [7 ]
机构
[1] Nobilon Int BV, Dept Virol R&D, NL-5830 AH Boxmeer, Netherlands
[2] JAS Biol Ltd, Annex, Ctr Vet Sci, Cambridge CB3 0ES, England
[3] Intervet Int BV, Dept Bacteriol R&D, Milton Keynes, Bucks, England
[4] Intervet Int BV, Dept Regulatory Affairs, NL-5831 AN Boxmeer, Netherlands
[5] Intervet Int BV, Dept Vaccine Technol & Immunol, NL-5831 AN Boxmeer, Netherlands
[6] Nobilon Int BV, Dept Qual Operat, NL-5830 AH Boxmeer, Netherlands
[7] Intervet Int BV, Dept Parasitol R&D, NL-5831 AN Boxmeer, Netherlands
关键词
Vaccine; Industry; Regulatory; Good manufacturing practice (GMP);
D O I
10.1016/j.tvjl.2007.11.009
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Veterinary vaccines currently available in Europe and in other parts of the world are developed by the veterinary pharmaceutical industry. The development of a vaccine for veterinary use is an economic endeavour that takes many years. There are many obstacles along the path to the successful development and launch of a vaccine. The industrial development of a vaccine for veterinary use usually starts after the proof of concept that is based on robust academic research. A vaccine can only be made available to the veterinary community once marketing authorisation has been granted by the veterinary authorities. This review gives a brief description of the regulatory requirements which have to be fulfilled before a vaccine can be admitted to the market. Vaccines have to be produced in a quality controlled environment to guarantee delivery of a product of consistent quality with well defined animal and consumer safety and efficacy characteristics. The regulatory and manufacturing legislative framework in which the development takes place is described, as well as the trend in developments in production systems. Recent developments in bacterial, viral and parasite vaccine research and development are also addressed and the development of novel adjuvants that use the expanding knowledge of immunology and disease pathology are described. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:7 / 20
页数:14
相关论文
共 91 条
[1]   Efficacy of the classical swine fever (CSF) marker vaccine Porcilis® Pesti in pregnant sows [J].
Ahrens, U ;
Kaden, V ;
Drexler, C ;
Visser, N .
VETERINARY MICROBIOLOGY, 2000, 77 (1-2) :83-97
[2]   Porcine circoviruses: a review [J].
Allan, GM ;
Ellis, JA .
JOURNAL OF VETERINARY DIAGNOSTIC INVESTIGATION, 2000, 12 (01) :3-14
[3]   Comparison of the efficacy of three commercial bacterins in preventing canine leptospirosis [J].
André-Fontaine, G ;
Branger, C ;
Gray, AW ;
Klassen, HLBM .
VETERINARY RECORD, 2003, 153 (06) :165-169
[4]  
[Anonymous], VICHGL9
[5]  
Boulter N, 2000, ADV PARASIT, V44, P41
[6]  
BROWNLIE J, 1996, VET REC, V137, P582
[7]   Mycobacterium tuberculosis heat shock proteins use diverse toll-like receptor pathways to activate pro-inflammatory signals [J].
Bulut, Y ;
Michelsen, KS ;
Hayrapetian, L ;
Naiki, Y ;
Spallek, R ;
Singh, M ;
Arditi, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (22) :20961-20967
[8]   TOXOPLASMOSIS - THE 1ST COMMERCIAL VACCINE [J].
BUXTON, D .
PARASITOLOGY TODAY, 1993, 9 (09) :335-337
[9]   The challenge of avian influenza to the veterinary community [J].
Capua, Ilaria ;
Alexander, Dennis J. .
AVIAN PATHOLOGY, 2006, 35 (03) :189-205
[10]  
CHUNMEI J, 2005, VET MICROBIOL, V109, P179